In the News March 30, 2017

The Pink Sheet | Off-Label Opioid Promotion: US FDA 'Does Not Object' To Intranasal Deterrence Data, Egalet Says

Marc Scheineson comments on the U.S. Food and Drug Administration’s approval of promotional materials highlighting a drug’s novel and generic abuse-deterrent formulation.
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222
This website uses cookies to improve functionality and performance. By continuing to browse this site, you are consenting to the use of cookies on this website. For details, see our Privacy Statement